Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy.
brentuximab vedotin
chemotherapy‐induced peripheral neuropathy
chronic inflammatory demyelinating polyradiculoneuropathy
immune‐related adverse events
inflammatory neuropathy
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
21 Mar 2024
21 Mar 2024
Historique:
revised:
05
03
2024
received:
15
11
2023
accepted:
06
03
2024
medline:
21
3
2024
pubmed:
21
3
2024
entrez:
21
3
2024
Statut:
aheadofprint
Résumé
Peripheral neuropathy is a frequent complication of brentuximab vedotin (BV), used in CD30+ lymphoma treatment. Classic BV-induced neuropathy (BV-CN) is a mild distal sensory axonal polyneuropathy. Severe BV-induced inflammatory neuropathies (BV-IN) have been described. BV-IN contribute to lymphoma-associated morbidity but might be immunotherapy-responsive. Our primary objective was to evaluate the rate of BV-IN. Our secondary objectives were to determine risk factors and warning signs. We conducted a retrospective cohort study on all patients treated with BV at our center between April 2014 and September 2021. Clinical, biological, and electrophysiological data were collected. BV-induced neuropathy was defined as the occurrence of neuropathy up to 3 months after BV discontinuation. BV-IN was defined with criteria adapted from European Academy of Neurology/Peripheral Nerve Society 2021 electrodiagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Other neuropathies were classified as BV-CN. Among 83 patients, 41 (49%) developed neuropathy: 35 BV-CN and 6 BV-IN. Thus, the rate of BV-IN was 7.2%. Compared to patients with BV-CN, no predisposing factor was identified. However, patients with BV-IN more frequently presented muscle weakness (67% vs. 5.7%, p < 0.05), gait disorders (83% vs. 20%, p < 0.05), or acute or subacute onset (67% vs. 14%, p < 0.05). BV-IN was frequently more severe (Common Terminology Criteria for Adverse Events grade ≥3; 50% vs. 0%, p < 0.05). Four patients were treated with immunotherapy. Brentuximab vedotin-induced neuropathy is an overlooked complication. Based on four easily identifiable "red flags", we provide an algorithm to help non-neurologist physicians that care for BV-treated patients to detect BV-IN. The aim of the algorithm is to decrease the diagnostic and management delay of this disabling neuropathy.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Peripheral neuropathy is a frequent complication of brentuximab vedotin (BV), used in CD30+ lymphoma treatment. Classic BV-induced neuropathy (BV-CN) is a mild distal sensory axonal polyneuropathy. Severe BV-induced inflammatory neuropathies (BV-IN) have been described. BV-IN contribute to lymphoma-associated morbidity but might be immunotherapy-responsive. Our primary objective was to evaluate the rate of BV-IN. Our secondary objectives were to determine risk factors and warning signs.
METHODS
METHODS
We conducted a retrospective cohort study on all patients treated with BV at our center between April 2014 and September 2021. Clinical, biological, and electrophysiological data were collected. BV-induced neuropathy was defined as the occurrence of neuropathy up to 3 months after BV discontinuation. BV-IN was defined with criteria adapted from European Academy of Neurology/Peripheral Nerve Society 2021 electrodiagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Other neuropathies were classified as BV-CN.
RESULTS
RESULTS
Among 83 patients, 41 (49%) developed neuropathy: 35 BV-CN and 6 BV-IN. Thus, the rate of BV-IN was 7.2%. Compared to patients with BV-CN, no predisposing factor was identified. However, patients with BV-IN more frequently presented muscle weakness (67% vs. 5.7%, p < 0.05), gait disorders (83% vs. 20%, p < 0.05), or acute or subacute onset (67% vs. 14%, p < 0.05). BV-IN was frequently more severe (Common Terminology Criteria for Adverse Events grade ≥3; 50% vs. 0%, p < 0.05). Four patients were treated with immunotherapy.
CONCLUSIONS
CONCLUSIONS
Brentuximab vedotin-induced neuropathy is an overlooked complication. Based on four easily identifiable "red flags", we provide an algorithm to help non-neurologist physicians that care for BV-treated patients to detect BV-IN. The aim of the algorithm is to decrease the diagnostic and management delay of this disabling neuropathy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16285Informations de copyright
© 2024 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778‐784. doi:10.1038/nbt832
Connors JM, Ansell SM, Fanale M, Park SI, Younes A. Five‐year follow‐up of brentuximab vedotin combined with ABVD or AVD for advanced‐stage classical Hodgkin lymphoma. Blood. 2017;130(11):1375‐1377. doi:10.1182/blood-2017-05-784678
Mariotto S, Tecchio C, Sorio M, et al. Clinical and neurophysiological serial assessments of brentuximab vedotin‐associated peripheral neuropathy. Leuk Lymphoma. 2019;60(11):2806‐2809. doi:10.1080/10428194.2019.1605068
Pastorelli F, Derenzini E, Plasmati R, et al. Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2013;54(10):2318‐2321. doi:10.3109/10428194.2013.773997
Fargeot G, Dupel‐Pottier C, Stephant M, et al. Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies. J Neurol Neurosurg Psychiatry. 2020;91(7):786‐788. doi:10.1136/jnnp-2020-323124
European Medicines Agency. Adcetris—Summary of Product Characteristics. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris#product‐information‐section
van den Bergh PYK, Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force—Second revision. Eur J Neurol. 2021;28(11):3556‐3583. doi:10.1111/ene.14959
van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force—Second revision. J Peripher Nerv Syst. 2021;26(3):242‐268. doi:10.1111/jns.12455
Sjoberg DD, Whiting K, Curry M, Lavery JA, Larmarange J. Reproducible summary tables with the gtsummary package. R J. 2021;13(1):570. doi:10.32614/RJ-2021-053
van Heertum RL, Scarimbolo R, Wolodzko JG, et al. Lugano 2014 criteria for assessing FDG‐PET/CT in lymphoma: an operational approach for clinical trials. Drug Des Devel Ther. 2017;11:1719‐1728. doi:10.2147/DDDT.S136988
Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem‐cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet. 2015;385(9980):1853‐1862. doi:10.1016/S0140-6736(15)60165-9
Velasco R, Domingo‐Domenech E, Sureda A. Brentuximab‐induced peripheral neurotoxicity: a multidisciplinary approach to manage an emerging challenge in Hodgkin lymphoma therapy. Cancer. 2021;13(23):6125. doi:10.3390/cancers13236125
Broers MC, de Wilde M, Lingsma HF, van der Lei J, Verhamme KMC, Jacobs BC. Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in the Netherlands. J Peripher Nerv Syst. 2022;27:182‐188. doi:10.1111/jns.12502
Rajabally YA, Afzal S, Loo LK, Goedee H. Application of the 2021 EAN/PNS criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2022;93:1247‐1252. doi:10.1136/jnnp-2022-329633
Shahrizaila N, Lehmann HC, Kuwabara S. Guillain–Barré syndrome. Lancet. 2021;397(10280):1214‐1228. doi:10.1016/S0140-6736(21)00517-1
Mathey EK, Park SB, Hughes RAC, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86(9):973‐985. doi:10.1136/jnnp-2014-309697
Oh SJ, Kurokawa K, de Almeida DF, Ryan HF, Claussen GC. Subacute inflammatory demyelinating polyneuropathy. Neurology. 2003;61(11):1507‐1512. doi:10.1212/01.WNL.0000096166.28131.4C
Oh SJ, Lu L, Alsharabati M, Morgan MB, King P. Chronic inflammatory axonal polyneuropathy. J Neurol Neurosurg Psychiatry. 2020;91(11):1175‐1180. doi:10.1136/jnnp-2020-323787
Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P. Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol. 1992;49(6):612‐616. doi:10.1001/archneur.1992.00530300044009
Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti‐programmed death 1 (PD‐1) antibodies. JAMA Neurol. 2017;74(10):1216‐1222. doi:10.1001/jamaneurol.2017.1912
Spain L, Walls G, Julve M, et al. Neurotoxicity from immune‐checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol. 2017;28(2):377‐385. doi:10.1093/annonc/mdw558
Chen X, Haggiagi A, Tzatha E, DeAngelis LM, Santomasso B. Electrophysiological findings in immune checkpoint inhibitor‐related peripheral neuropathy. Clin Neurophysiol. 2019;130(8):1440‐1445. doi:10.1016/j.clinph.2019.03.035
Marini A, Bernardini A, Gigli GL, et al. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology. 2021;96(16):754‐766. doi:10.1212/WNL.0000000000011795
Fonseca E, Cabrera‐Maqueda JM, Ruiz‐García R, et al. Neurological adverse events related to immune‐checkpoint inhibitors in Spain: a retrospective cohort study. Lancet Neurol. 2023;22(12):1150‐1159. doi:10.1016/S1474-4422(23)00335-6
Kapoor M, Compton L, Shaw H, et al. 197 checkpoint inhibitor associated neuritis a novel pathological entity. J Neurol Neurosurg Psychiatry. 2022;93:e2.159. doi:10.1136/jnnp-2022-abn2.241
Corbin ZA, Nguyen‐Lin A, Li S, et al. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary syndrome. J Neuro‐Oncol. 2017;132(3):439‐446. doi:10.1007/s11060-017-2389-9
Pettit GR. The dolastatins. Fortschritte Chem Org Naturst. 1997;70:1‐79. doi:10.1007/978-3-7091-6551-5_1
Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non‐Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254‐e265. doi:10.1016/S2352-3026(19)30026-2
Vahdat LT, Schmid P, Forero‐Torres A, et al. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple‐negative breast cancer (“METRIC”): a randomized multicenter study. NPJ Breast Cancer. 2021;7(1):57. doi:10.1038/s41523-021-00244-6
Ebrahim A, Elmore K, Shin S. Chronic inflammatory demyelinating polyradiculoneuropathy associated with Enfortumab Vedotin (P9‐13.006). Neurology. 2022;98(18 Supplement):3811. https://n.neurology.org/content/98/18_Supplement/3811
Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. In: Grewal IS, ed. Therapeutic Targets of the TNF Superfamily. Vol 647. Advances in Experimental Medicine and Biology. Springer; 2009:174‐185. doi:10.1007/978-0-387-89520-8_12
Shinoda K, Sun X, Oyamada A, et al. CD30 ligand is a new therapeutic target for central nervous system autoimmunity. J Autoimmun. 2015;57:14‐23. doi:10.1016/j.jaut.2014.11.005
Seror R, Richez C, Sordet C, et al. Pattern of demyelination occurring during anti‐TNF‐α therapy: a French national survey. Rheumatology. 2013;52(5):868‐874. doi:10.1093/rheumatology/kes375
Tsouni P, Bill O, Truffert A, et al. Anti‐TNF alpha medications and neuropathy. J Peripher Nerv Syst. 2015;20(4):397‐402. doi:10.1111/jns.12147
Oflazoglu E, Stone IJ, Gordon KA, et al. Macrophages contribute to the antitumor activity of the anti‐CD30 antibody SGN‐30. Blood. 2007;110(13):4370‐4372. doi:10.1182/blood-2007-06-097014
Kiefer R, Kieseier BC, Stoll G, Hartung HP. The role of macrophages in immune‐mediated damage to the peripheral nervous system. Prog Neurobiol. 2001;64(2):109‐127. doi:10.1016/S0301-0082(00)00060-5
Koike H, Nishi R, Ikeda S, et al. Ultrastructural mechanisms of macrophage‐induced demyelination in CIDP. Neurology. 2018;91(23):1051‐1060. doi:10.1212/WNL.0000000000006625
Wanschitz J, Maier H, Lassmann H, Budka H, Berger T. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain–Barré syndrome. Brain. 2003;126(9):2034‐2042. doi:10.1093/brain/awg207